Inger Lund Pedersen

Title: Inger Lund Pedersen: Innovator in Antibody Therapeutics

Introduction

Inger Lund Pedersen is a notable inventor based in Vanløse, Denmark. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of six patents to her name, her work focuses on therapeutic applications that can improve patient outcomes.

Latest Patents

One of her latest patents is titled "Antibodies against human NKG2D and uses thereof." This invention provides isolated anti-human NKG2D monoclonal antibodies that are useful for therapeutic applications in humans. The antibodies are typically fully human or humanized to minimize the risk of immune responses when administered to patients. Preferred antibodies include human monoclonal antibodies MS and 21F2. The patent also describes other antigen-binding molecules, such as antibody fragments, derivatives, and multi-specific molecules that can be designed or derived from these antibodies.

Career Highlights

Inger has worked with prominent companies in the biotechnology sector, including Novo Nordisk A/S and Argos Therapeutics, Inc. Her experience in these organizations has allowed her to contribute to groundbreaking research and development in antibody therapeutics.

Collaborations

Throughout her career, Inger has collaborated with esteemed colleagues, including Peter Andreas Nicolai Reumert Wagtmann and Lars Anders Svensson. These collaborations have further enhanced her research and innovation in the field.

Conclusion

Inger Lund Pedersen is a pioneering inventor whose work in monoclonal antibodies has the potential to transform therapeutic applications in medicine. Her contributions continue to impact the biotechnology landscape positively.